B. Braun Melsungen AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Subsidiary

Established: 1839-01-01

Employees: 10K

Market Cap: -

Website: https://www.bbraun.com/en.html

Clinical Trials

Usability of Blood Glucose Control With the Space TGC System in Medical ICU Patients

Not Applicable

Completed

Conditions: Critical Illness

Interventions: Device: Space TGC

First Posted Date: 2010-07-16

Last Posted Date: 2011-08-18

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 20

Registration Number: NCT01164449

Locations: 🇨🇭
University Hospital Zürich, Zürich, Switzerland

Feasibility of Blood Glucose Control With the Space TGC System in Medical ICU Patients

Not Applicable

Completed

Conditions: Critical Illness

Interventions: Device: Space TGC

First Posted Date: 2010-07-16

Last Posted Date: 2011-02-09

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 20

Registration Number: NCT01164423

Locations: 🇦🇹
Medizinische Universität Graz, Department of Internal Medicine, Graz, Austria

Parenteral Nutrition With Intravenous and Oral Fish Oil for Intensive Care Patients

Phase 3

Completed

Conditions: Critical Illness

Interventions: Drug: Nutriflex Lipid special + Pulmocare
Drug: Nutriflex Omega special + Oxepa

First Posted Date: 2010-07-15

Last Posted Date: 2018-04-27

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 100

Registration Number: NCT01162928

Locations: 🇮🇱
Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel

Feasibility of Tight Blood Glucose Control With the Space TGC System in Surgical ICU Patients

Not Applicable

Completed

Conditions: Critical Illness

Interventions: Device: Space TGC

First Posted Date: 2010-06-22

Last Posted Date: 2010-11-02

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 20

Registration Number: NCT01146847

Locations: 🇩🇪
Klinikum Ludwigshafen am Rhein gGmbH, Klinik für Anästhesiologie und Operative Intensivmedizin, Ludwigshafen, Germany

Plasma Volume Replacement (PVR) Therapy With Colloid and Crystalloid Solutions

Phase 4

Completed

Conditions: Surgery of the Pancreatic Head
Plasma Volume Replacement

Interventions: Drug: HES 10%
Drug: HES 6%
Drug: balanced electrolyte solution

First Posted Date: 2010-05-05

Last Posted Date: 2016-12-23

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 63

Registration Number: NCT01117649

Locations: 🇩🇪
Klinik für Anästhesie und operative Intensivmedizin, Charité-Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Klinik für Anästhesie, operative Intensivmedizin und Schmerztherapie, Humboldt Klinikum, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn, Bonn, Germany

Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)

Phase 4

Terminated

Conditions: Renal Insufficiency

Interventions: Drug: HES 130/0.42 + electrolyte solution
Drug: Albumin + electrolyte solution

First Posted Date: 2009-07-09

Last Posted Date: 2010-09-28

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 2

Registration Number: NCT00936247

Locations: 🇩🇪
Klinik für Anästhesiologie und operative Intensivmedizin, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany
🇩🇪
Klinikum Mannheim gGmbH, Klinik für Anästhesiologie und Operative Intensivmedizin, Mannheim, Germany

Blood Glucose Control Over an Extended Glucose Control Range in Postoperative Cardiac Surgery Patients in the Intensive Care Unit

Not Applicable

Completed

Conditions: Critical Illness

Interventions: Other: enhanced model predictive control algorithm (eMPC)

First Posted Date: 2009-04-16

Last Posted Date: 2010-02-05

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 20

Registration Number: NCT00882427

Locations: 🇬🇧
Royal Brompton Hospital and Harefield NHS Trust, London, United Kingdom

Non-Interventional (Observational) Post-Authorization Safety Study of HES 130/0.42 in Paediatric Patients

Completed

Conditions: Surgery

Interventions: Drug: HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)

First Posted Date: 2008-12-11

Last Posted Date: 2009-05-19

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 1130

Registration Number: NCT00806533

Locations: 🇨🇿
Clinic of Children's Anaesthesiology and Resuscitation, Brno, Czech Republic
🇦🇹
Donauspital SMZ-OST, Vienna, Austria
🇨🇿
Clinic of Anaesthesiology and Resuscitation, Praha, Czech Republic

and more 7 locations

Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery

Phase 3

Completed

Conditions: GI Cancer

Interventions: Drug: MLF 541
Drug: Lipofundin MCT

First Posted Date: 2008-11-26

Last Posted Date: 2011-06-09

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 100

Registration Number: NCT00798447

Locations: 🇨🇳
National Taiwan University Hospital Taipei, Taipei, Taiwan
🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Blood Glucose Control With A Software-Algorithm In Intensive Care Unit (ICU) Patients

Not Applicable

Completed

Conditions: Critical Illness

Interventions: Other: enhanced model predictive control algorithm (eMPC)

First Posted Date: 2008-08-14

Last Posted Date: 2009-04-16

Lead Sponsor: B. Braun Melsungen AG

Target Recruit Count: 20

Registration Number: NCT00735163

Locations: 🇦🇹
Medical University Graz, Graz, Austria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy